Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
about
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Biomarkers of Angiogenesis in Colorectal CancerPharmacogenetic biomarkers for the prediction of response to antiangiogenic treatmentDecreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patientsPrognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trialeNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphismsThe relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer.Biomarker in Colorectal Cancer.Vascular endothelial growth factor and hypoxia-inducible factor-1α gene polymorphisms and coronary collateral formation in patients with coronary chronic total occlusionsTumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer.Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer.Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.Angiogenesis in neuroendocrine tumors: therapeutic applications.VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Bevacizumab: a review of its use in advanced cancer.Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).[Advances of VEGR gene polymorphism and its clinical values in lung cancer]."Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer.Association of vascular endothelial growth factor--a gene polymorphisms and haplotypes with breast cancer metastases.Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.
P2860
Q26752752-833BF8FD-827F-4450-B1D9-B67D5ECB8B5AQ26778891-BD283478-52E4-4F08-9E72-3228A3F9798DQ26996793-16DE76B5-B5C3-4F9C-A431-4E260948F6CDQ27853168-360032B6-5C2B-4C1B-8F4E-F33614320C0DQ30537414-5EFE882D-8557-4D4F-8927-BB36525F5B50Q30986269-DAE983E3-5F89-48D5-A66D-1C2FF6C00100Q33616231-CD7E4E00-13F7-4EF0-BBD1-D17DC28BED26Q34572068-177FB387-8019-4D84-AF8F-559829B0374AQ35217801-FD0BBECB-43AE-4BD5-8886-E4F779EA5B35Q36219923-383C2C16-0427-4313-B7D2-E4AF7F37FAFAQ36630521-0B3EB369-3D01-4943-84FE-8A8D0D1CC3F9Q37114675-48E88FEE-DE54-4C5A-8C0B-C7DEDD1036D0Q37221880-CAED4C46-FC70-436E-B343-F1B9A42E113EQ37561000-D6FAD107-3F7E-42E0-8041-42C8DD03CA23Q37706985-81A7471B-2AC8-4422-BE27-3DAF52C91A07Q37961087-8545BF5E-175F-4CF7-A1DD-C7CB356F0880Q37969851-7EB9FDC4-1521-4912-A6EC-669F1C022788Q38005887-41A33643-0FAA-4E04-B7A7-738552F3035AQ38148602-69FF5CDD-EF34-4763-A058-332D80C65097Q38166233-FEA24368-F62F-482A-9A2B-FFD675947C3BQ38260176-DC003779-2F89-4DE3-B65D-D98356D1842EQ38307997-078DDC73-BEA6-4A7F-B97B-92F7100EBD19Q38941928-A31B01E7-11A5-4743-A5E0-624C69D6FFC0Q41715428-5D5943DB-08E1-4DA0-ACA1-05AC889259C7Q41892380-8CA3F51A-14E1-41C3-B8D9-461FC6413EE0Q44512725-3AE79C24-B621-48C6-92EC-4E5B4949CF1FQ45828775-5325F8EF-5A02-42B3-BAF7-93C52EFCFF13Q48207420-86116A90-FDE4-4497-A788-1C40A3FB502EQ48587745-0E68B925-2E32-4191-A88A-46FB4E0A59B7Q54196655-34A82A9B-E4F2-4624-9051-006761FDF637Q54335658-122DF79B-89C0-45DE-94AF-543FB0226539
P2860
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Predictive value of VEGF gene ...... , irinotecan, and bevacizumab.
@en
Predictive value of VEGF gene ...... , irinotecan, and bevacizumab.
@nl
type
label
Predictive value of VEGF gene ...... , irinotecan, and bevacizumab.
@en
Predictive value of VEGF gene ...... , irinotecan, and bevacizumab.
@nl
prefLabel
Predictive value of VEGF gene ...... , irinotecan, and bevacizumab.
@en
Predictive value of VEGF gene ...... , irinotecan, and bevacizumab.
@nl
P2093
P2860
P1476
Predictive value of VEGF gene ...... , irinotecan, and bevacizumab.
@en
P2093
Annalisa Savonarola
Fiorella Guadagni
Giorgia Ludovici
Girolamo Del Monte
Italia Grenga
Maria Laura De Marchis
Mario Roselli
Michele Schirru
Raffaele Palmirotta
Vincenzo Formica
P2860
P2888
P304
P356
10.1007/S00384-010-1108-1
P577
2010-12-29T00:00:00Z
P5875
P6179
1000061546